Stocktoria
ACADIA PHARMACEUTICALS INC ACAD
ACADIA PHARMACEUTICALS INC financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.1B | $957.8M | $726.4M | $517.2M | $484.1M | $441.8M | $339.1M | $223.8M | $124.9M | $17.3M |
| Gross profit | — | — | $684.8M | $507.1M | $473.3M | $431.5M | $327.7M | $211.4M | $115.8M | $14.3M |
| R&D expense | $328.8M | $303.2M | $351.6M | $361.6M | $239.4M | $319.1M | $240.4M | $187.2M | $149.2M | $99.3M |
| SG&A expense | $548.9M | $488.4M | $406.6M | $369.1M | $396.0M | $388.7M | $325.6M | $265.8M | $255.1M | $186.5M |
| Operating income | $104.8M | $230.8M | -$73.4M | -$223.6M | -$170.4M | -$286.6M | -$246.5M | -$247.4M | -$292.4M | -$272.8M |
| Income tax | -$252.1M | $31.6M | $10.2M | $2.5M | $351,000 | $611,000 | $876,000 | $1.3M | $1.1M | $1.3M |
| Net income | $391.0M | $226.5M | -$61.3M | -$216.0M | -$167.9M | -$281.6M | -$235.3M | -$245.2M | -$289.4M | -$271.4M |
| EPS (diluted) | $2.30 | $1.36 | $-0.37 | $-1.34 | $-1.05 | $-1.79 | — | — | — | — |
| Operating cash flow | $109.8M | $157.7M | $16.7M | -$114.0M | -$125.7M | -$136.2M | -$151.1M | -$167.5M | -$217.9M | -$210.4M |
| Free cash flow | $105.1M | $157.2M | $16.7M | -$114.0M | -$126.8M | -$143.8M | -$152.3M | -$169.6M | -$218.7M | -$211.9M |
| Cash & equivalents | $177.7M | $319.6M | $188.7M | $114.8M | $147.4M | $326.0M | $189.7M | $134.8M | $69.4M | $163.6M |
| Inventory | $111.4M | $91.7M | $40.4M | $11.6M | $14.1M | $9.7M | $6.3M | $4.1M | $5.2M | $4.2M |
| Total assets | $1.6B | $1.2B | $749.0M | $587.8M | $700.1M | $782.6M | $783.2M | $540.2M | $384.5M | $561.2M |
| Total liabilities | $336.8M | $455.0M | $317.2M | $187.4M | $159.2M | $155.6M | $84.0M | $61.1M | $49.2M | $42.7M |
| Shareholders' equity | $1.2B | $732.8M | $431.8M | $400.4M | $540.9M | $627.0M | $699.1M | $479.1M | $335.3M | $518.4M |
Growth · year-over-year · Revenue CAGR 58.1%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +11.9% | +31.8% | +40.4% | +6.8% | +9.6% | +30.3% | +51.5% | +79.2% | +620.7% | +28311.5% |
| Net income growth | +72.7% | — | — | — | — | — | — | — | — | — |
| EPS growth | +69.1% | — | — | — | — | — | — | — | — | — |
| Free cash flow growth | -33.1% | +844.0% | — | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.